✦ LIBER ✦

Results of a Retrospective Single Institution Analysis of Targeted Skeletal Radiotherapy with 166Holmium-DOTMP as Conditioning Regimen for Autologous Stem Cell Transplant for Patients with Multiple Myeloma. Impact on Transplant Outcomes

✍ Scribed by Anna V. Christoforidou; Rima M. Saliba; Patricia Williams; Muzaffar Qazilbash; Linda Roden; Ana Aleman; Donna Weber; Floralyn Mendoza; Donald Podoloff; Richard Wendt III; Hazel Breitz; Raymond Alexanian; Richard Champlin; Sergio Giralt

Book ID: 116279559
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 211 KB
Volume: 13
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2006.12.448

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Results of a Retrospective Single-Instit

Results of a Retrospective Single-Institution Analysis of Oral Mucositis in Patients Undergoing Melphalan-Based Autologous Stem Cell Transplant for Multiple Myeloma

✍ RODRIGUES, GUSTAVO HENRIQUE CAMPOS; DE MELO, LEILA MARIA MAGALHÃES PESSOA; GUOLL 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 78 KB

144: Autologous stem cell transplantatio

144: Autologous stem cell transplantation (ASCT) for patients with multiple myeloma (MM): Impact of the degree of plasma cell bone marrow infiltration on mobilization kinetic and transplant outcomes

✍ A. Go; S.A. Gregory; P. Venugopal; J. Shammo; B. McLeod; H.C. Fung 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 72 KB

Melphalan 180mg/m2 Can Be Safely Adminis

Melphalan 180mg/m2 Can Be Safely Administered as Conditioning Regimen Prior to an Autologous Stem Cell Transplantation in Multiple Myeloma Patients with Creatinine Clearance ≤60ml/min/1.73 m2 with Use of Palifermin for Cytoprotection: Results of a Phase I Trial

✍ M.H. Abidi; R. Agarwal; N. Tageja; L. Ayash; M. Ventimiglia; A. Deol; Z. Al-Kadh 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 84 KB

Melphalan 180 mg/m2 Can Be Safely Admini

Melphalan 180 mg/m2 Can Be Safely Administered As Conditioning Regimen before an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Creatinine Clearance 60 mL/min/1.73 m2 or Lower with Use of Palifermin for Cytoprotection: Results of a Phase I Trial

✍ Abidi, Muneer H.; Agarwal, Rishi; Ayash, Lois; Deol, Abhinav; Al-Kadhimi, Zaid; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 139 KB